Trial Profile
A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Efficacy and Safety of STG320 Sublingual Tablets of House Dust Mite (HDM) Allergen Extracts in Adults and Adolescents With HDM-associated Allergic Rhinitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Apr 2022
Price :
$35
*
At a glance
- Drugs S 524101 (Primary)
- Indications Allergic rhinitis
- Focus Registrational; Therapeutic Use
- Sponsors Stallergenes Greer plc; Stallergenes SA
- 04 May 2020 According to a Stallergenes Greer media release, it announces the submission of a marketing authorisation application for STAGR320, its sublingual house dust mite (HDM) immunotherapy (SLIT) tablet, via a European decentralized procedure.
- 20 Nov 2018 According to a Stallergenes Greer plc media release, a full assessment of the data is ongoing, with detailed results expected to be presented at future scientific congresses, including the annual European Academy of Allergy and Clinical Immunology (EAACI) Congress.
- 20 Nov 2018 Primary endpoint has been met. (Total Combined Score), according to a Stallergenes Greer plc media release.